Researchers from the Icahn School of Medicine at Mount Sinai in New York have discovered a novel approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity-a ...

TIXiMED, Inc., a clinical-stage pharmaceutical company developing innovative therapies for diabetes based on the breakthrough ...

A study led by researchers at Stanford Medicine has shown that differences in blood sugar responses to certain carbohydrates depend on details of an individual’s metabolic health status, including ...

Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.

Researchers from the Icahn School of Medicine at Mount Sinai in New York have discovered a novel approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity—a ...

Type 2 diabetes (T2D) is a chronic and widely prevalent condition characterized by a progressive loss of glycemic control driven by both insulin resistance and β-cell dysfunction. The disease has long ...

LOS ANGELES — Scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and a leading research center for diabetes and other ...

Deep learning analysis of high-resolution pancreatic tissue images has identified subtle structural changes linked to beta cell dysfunction which offers novel insight into the development of type ...